Clinical Trial Grants support Phase II/III clinical trials of novel, high-potential treatments for MND/ALS within the Australian Clinical Trials Consortium.   

These grants are awarded with an offer of up to AUD $1,800,000 (Phase II/III trial), with project performance of up to 3 years.  

Eligibility: Applications are open to MND/ALS researchers globally. Australian trial sites and participants are mandatory.   

Click below to download a copy of: 

Videos to guide your submission using the FightMND Grant Management System – Fluxx: